Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Coherus Oncology, Inc. has received a consensus rating of "Hold" from five research firms, with one analyst issuing a sell rating, another a hold rating, and three assigning a buy rating.
• The average target price from analysts covering Coherus is $4.5125, despite the stock trading down 1.2% to $1.64 with a recent trading volume of 713,898 shares.
• Institutional investors currently hold 72.82% of Coherus Oncology's stock, with significant transactions from various hedge funds in recent months.

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have been given an average rating of "Hold" by the five research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.5125.

CHRS has been the subject of several analyst reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Coherus Oncology in a research note on Saturday, September 27th. Maxim Group upgraded shares of Coherus Oncology from a "hold" rating to a "buy" rating and set a $4.00 price objective for the company in a research note on Thursday, September 4th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC grew its stake in Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company's stock valued at $44,000 after buying an additional 10,000 shares in the last quarter. Jane Street Group LLC purchased a new position in Coherus Oncology in the 2nd quarter valued at approximately $46,000. Invesco Ltd. boosted its holdings in Coherus Oncology by 11.5% in the 2nd quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company's stock valued at $152,000 after purchasing an additional 21,550 shares during the period. Panagora Asset Management Inc. bought a new position in Coherus Oncology in the 2nd quarter valued at $581,000. Finally, Tejara Capital Ltd boosted its holdings in Coherus Oncology by 1.7% in the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company's stock valued at $511,000 after purchasing an additional 11,552 shares during the period. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus Oncology Trading Down 1.2%

NASDAQ:CHRS traded down $0.02 on Friday, hitting $1.64. The stock had a trading volume of 713,898 shares, compared to its average volume of 1,300,942. The company has a current ratio of 1.44, a quick ratio of 1.43 and a debt-to-equity ratio of 0.31. Coherus Oncology has a 1 year low of $0.66 and a 1 year high of $2.43. The firm's fifty day simple moving average is $1.23 and its two-hundred day simple moving average is $0.99.

About Coherus Oncology

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.